Literature DB >> 24098903

Strategic management of keloid disease in ethnic skin: a structured approach supported by the emerging literature.

S Ud-Din1, A Bayat.   

Abstract

Keloid disease (KD) is a common, benign, dermal fibroproliferative growth of unknown aetiology. Lesions tend to grow over time; they often recur following therapy and do not regress spontaneously. KD causes considerable discomfort due to pain, pruritus and inflammation, and a significant psychosocial impact with reduced quality of life. It is unique to humans and occurrence is higher in individuals with dark, pigmented, ethnic skin. There is a strong familial heritability, with a high ethnic predisposition in individuals of African, Asian and Hispanic descent. High recurrence rates and unknown resolution rates present a major problem for both the patient and clinician. Many treatment modalities exist; however, there is no single advocated therapy. Therefore, the aim of this review was to explore the most current literature regarding the range of treatment options for KD and to offer a structured approach in the management of KD, based on evidence and experience, to aid clinicians in their current practice. A focused history involving careful evaluation of the patient's symptoms, signs, quality of life and psychosocial well-being should direct targeted therapy, complemented with regular follow-up and re-evaluation. Many treatment modalities, such as intralesional steroid injection, silicone gel application, cryotherapy, lasers, 5-fluorouracil and, relatively recently, photodynamic therapy, are currently being used in clinical practice for the management of KD. Combination therapies have also been shown to be beneficial. However, there is a lack of robust, randomized, level-one, evidence-controlled trials evaluating these treatment options. Management of KD in ethnic pigmented skin remains a clinical challenge. Thus, a strategic approach with structured assessment, targeted therapy and focus on prevention of recurrence is highly recommended. Quality evidence is essential in order to tailor treatment effectively for the ethnic patient presenting with KD.
© 2013 The Authors BJD © 2013 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24098903     DOI: 10.1111/bjd.12588

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

Review 1.  Treatment of keloid scars using light-, laser- and energy-based devices: a contemporary review of the literature.

Authors:  E Forbat; F R Ali; F Al-Niaimi
Journal:  Lasers Med Sci       Date:  2017-10-18       Impact factor: 3.161

2.  Surgical management for large chest keloids with internal mammary artery perforator flap.

Authors:  Dan Xue; Huan Qian
Journal:  An Bras Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.896

Review 3.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.

Authors:  Carmel B Nanthakumar; Richard J D Hatley; Seble Lemma; Jack Gauldie; Richard P Marshall; Simon J F Macdonald
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

4.  Gene-based evaluation of low-frequency variation and genetically-predicted gene expression impacting risk of keloid formation.

Authors:  Jacklyn N Hellwege; Shirley B Russell; Scott M Williams; Todd L Edwards; Digna R Velez Edwards
Journal:  Ann Hum Genet       Date:  2018-02-27       Impact factor: 1.670

5.  Role of chymase in the local renin-angiotensin system in keloids: inhibition of chymase may be an effective therapeutic approach to treat keloids.

Authors:  Ru Wang; Junjie Chen; Zhenyu Zhang; Ying Cen
Journal:  Drug Des Devel Ther       Date:  2015-08-28       Impact factor: 4.162

6.  The management of helical rim keloids with excision, split thickness skin graft and intralesional triamcinolone acetonide.

Authors:  Ibrahim Abdul Rasheed; Asuku E Malachy
Journal:  J Cutan Aesthet Surg       Date:  2014-01

7.  Intralesional cryotherapy versus excision and corticosteroids or brachytherapy for keloid treatment: study protocol for a randomised controlled trial.

Authors:  Eveline Bijlard; Reinier Timman; Gerda M Verduijn; Frank B Niessen; Johan W van Neck; Jan J V Busschbach; Marc A M Mureau
Journal:  Trials       Date:  2013-12-19       Impact factor: 2.279

8.  Evidence of selection as a cause for racial disparities in fibroproliferative disease.

Authors:  Jacklyn N Hellwege; Eric S Torstenson; Shirley B Russell; Todd L Edwards; Digna R Velez Edwards
Journal:  PLoS One       Date:  2017-08-08       Impact factor: 3.240

9.  Ginsenoside Rg3 inhibits keloid fibroblast proliferation, angiogenesis and collagen synthesis in vitro via the TGF‑β/Smad and ERK signaling pathways.

Authors:  Mengyao Tang; Weiwei Bian; Liying Cheng; Lu Zhang; Rong Jin; Wenbo Wang; Yuguang Zhang
Journal:  Int J Mol Med       Date:  2018-01-04       Impact factor: 4.101

10.  The Shear Wave Velocity on Elastography Correlates with the Clinical Symptoms and Histopathological Features of Keloids.

Authors:  Rino Aya; Satoko Yamawaki; Katsuhiro Yoshikawa; Yasuhiro Katayama; Tatsuki Enoshiri; Motoko Naitoh; Shigehiko Suzuki
Journal:  Plast Reconstr Surg Glob Open       Date:  2015-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.